Presenters: PD Dr. Arno Kromminga, SVP & Chief Scientific Officer at BioAgilytix and Dr. Daniel Worms, Associate Principal Investigator at BioAgilytix
Host: GE Healthcare
The assessment of unwanted immunogenicity is a key parameter in the development process of biological protein drugs. In this webinar, BioAgilytix’s experts Dr. Arno Kromminga and Dr. Daniel Worms discuss aspects of when and how to use the Biacore™ T200 SPR System to obtain a deeper understanding of unwanted immunogenicity. Learn more about the Biacore™ T200 system in this blog.
Learn how BioAgilytix provides the
See how our PK expertise complements our immunogenicity services by evaluating
Learn why we’re a trusted partner to
What are your specific assay needs? Let’s schedule a conversation to review your
questions and requirements with one of our scientists.
Learn how BioAgilytix provides the
See how our PK expertise complements our immunogenicity services by evaluating
Learn why we’re a trusted partner to
What are your specific assay needs? Let’s schedule a conversation to review your
questions and requirements with one of our scientists.
Platforms
Services